{
  "meta": {
    "analysis_date": "2025-09-22",
    "stage_breadth_mode": "US_LATE",
    "analysis_type": "us_life_sciences",
    "token_usage": {
      "prompt_tokens": 1054956,
      "completion_tokens": 14468,
      "total_tokens": 1069424
    }
  },
  "executive_summary": {
    "summary_bullets": [
      "Target: a prophylactic vaccine for salmon lice (Lepeophtheirus salmonis) in farmed Atlantic salmon; no sea‑lice vaccine is licensed in the United States as of July 30, 2025 per USDA‑APHIS CVB product catalogs.",
      "US treatment options rely on investigational or off‑label tools (e.g., emamectin benzoate SLICE via USFWS INAD 11‑370; hydrogen peroxide bath regimens via USFWS INAD 11‑669 for marine use; FDA‑approved 35% PEROX‑AID only for freshwater indications), underscoring a clear unmet need in Maine’s marine salmon farming footprint."
    ],
    "key_takeaway": "Regulatory path for a fish vaccine is defined under USDA‑APHIS CVB, and a well‑differentiated anti‑parasite vaccine that reduces lice attachment/fecundity would face limited direct US competition but a small domestic TAM; global relevance may be materially larger. Robust US‑specific market data for sea‑lice control are limited; proceed with staged validation and parallel global partnering.",
    "citation": "USDA‑APHIS CVB licensed biologics listings (no sea‑lice vaccine) and product summaries; FDA‑CVM 35% PEROX‑AID approvals; USFWS AADAP INAD pages for SLICE and PEROX‑AID; NOAA on US Atlantic salmon aquaculture footprint. ([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics/licensed-products?utm_source=openai))"
  },
  "unmet_need_and_market_overview": {
    "market_size": {
      "global": {
        "current_usd": null,
        "cagr_percent": null,
        "five_year_usd_out": null,
        "citation": ""
      },
      "us": {
        "current_usd": null,
        "cagr_percent": null,
        "five_year_usd_out": null,
        "citation": ""
      }
    },
    "epidemiology": {
      "prevalence": {
        "global": "Sea lice (L. salmonis and Caligus spp.) are the most significant parasitic burden in marine salmon aquaculture globally, routinely requiring management on farms.",
        "us": "Sea lice are seasonally problematic in the Gulf of Maine marine net‑pen industry; Washington State ended commercial finfish net‑pen aquaculture in 2022–2025, concentrating US marine salmon aquaculture largely in Maine.",
        "citation": "Peer‑reviewed and institutional summaries; NOAA/UMaine note lice as key constraint; Washington DNR actions ended WA net‑pen operations. ([umaine.edu](https://umaine.edu/aquaculture/project/a-decision-support-system-for-sea-lice-management-in-salmon-aquaculture/?utm_source=openai))"
      },
      "incidence": {
        "global": null,
        "us": null,
        "citation": ""
      }
    }
  },
  "technological_differentiation": {
    "mechanism_of_action": {
      "description": "Prophylactic immunization against sea‑louse antigens (e.g., peptide/protein epitopes such as P33 or peroxiredoxin‑2) to elicit systemic and mucosal responses that reduce lice attachment, development, or fecundity on Atlantic salmon.",
      "citation": "Laboratory vaccine studies demonstrating reduced lice burdens after antigen‑specific vaccination in Atlantic salmon. ([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
    },
    "indication": "Prevention of salmon louse (Lepeophtheirus salmonis) infestation in farmed Atlantic salmon (Salmo salar).",
    "therapeutic_area": "Veterinary aquaculture – parasitology (ectoparasites).",
    "modality": "Vaccine (fish biologic regulated by USDA‑APHIS CVB).",
    "route_of_administration": null
  },
  "current_treatment_paradigm": {
    "if_indication_listed": {
      "first_line": [
        "Oral emamectin benzoate (SLICE) via USFWS INAD 11‑370: 50 µg/kg/day in feed for 7 consecutive days; investigational withdrawal period (IWP) 60 days."
      ],
      "second_line": [
        "Hydrogen peroxide immersion bath via USFWS INAD 11‑669 for marine finfish (sea‑cage options up to 400 mg/L for 45 min, up to 3 times/week); IWP 0 days."
      ],
      "third_line": [
        "Non‑medicinal/mechanical controls (thermal/mechanical delousing, freshwater baths, cleaner fish) with variable efficacy and documented fish‑welfare impacts."
      ],
      "citation": "USFWS AADAP INAD 11‑370 and 11‑669 protocols; peer‑reviewed assessments of thermal/mechanical delousing impacts. ([fws.gov](https://www.fws.gov/inad/slicer-emamectin-benzoate-11-370?utm_source=openai))"
    },
    "if_indication_not_listed": {
      "recommended_indications_based_on_moa": [
        ""
      ],
      "gold_standard_treatments_for_recommended_indications": [
        ""
      ],
      "citation": ""
    }
  },
  "competitive_landscape": {
    "clinical_stage_assets_global": [
      {
        "product": "Peptide vaccine (P33) against L. salmonis",
        "company": "Academic (Norway/Canada collaborations)",
        "modality": "Peptide/protein vaccine",
        "moa": "Anti‑parasite antigen elicits protective anti‑lice immunity",
        "stage": "Preclinical (challenge tanks)",
        "key_ref_or_nct": "Vaccines (MDPI) 2022;10(1):16",
        "citation": "([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
      },
      {
        "product": "Peroxiredoxin‑2 epitope vaccine",
        "company": "Academic",
        "modality": "Peptide/protein vaccine",
        "moa": "Targets louse peroxiredoxin epitope detected in infected salmon blood",
        "stage": "Preclinical (proof‑of‑concept)",
        "key_ref_or_nct": "Vaccines (MDPI) 2024;12(5):456",
        "citation": "([mdpi.com](https://www.mdpi.com/2076-393X/12/5/456?utm_source=openai))"
      },
      {
        "product": "Louse antigen discovery (e.g., P0 peptide) initiatives",
        "company": "Norwegian Veterinary Institute (Louse‑Off)",
        "modality": "Vaccine discovery",
        "moa": "Identification of salmon lice antigens for effective vaccines",
        "stage": "Discovery/preclinical",
        "key_ref_or_nct": "Project summary",
        "citation": "([vetinst.no](https://www.vetinst.no/en/research-and-innovation/past-research-projects/louse-off-1-sea-lice-vaccine-development-through-innovation?utm_source=openai))"
      }
    ],
    "on_market_drugs": [
      {
        "product": "35% PEROX‑AID (hydrogen peroxide)",
        "company": "Syndel USA",
        "modality": "Chemical bath",
        "moa": "Oxidative ectoparasiticide; approved for specified freshwater indications",
        "year_of_approval": "Initial 2007; supplemental approvals 2019",
        "sales_or_share_ref": "Approved aquaculture drug listing; not indicated for sea‑lice in seawater (marine use currently under INAD)",
        "citation": "([fda.gov](https://www.fda.gov/animal-veterinary/aquaculture/approved-aquaculture-drugs?utm_source=openai))"
      },
      {
        "product": "Emamectin benzoate (SLICE) – US use via INAD 11‑370",
        "company": "Merck Animal Health (Intervet) – investigational in US",
        "modality": "In‑feed avermectin",
        "moa": "Glutamate‑gated chloride channel modulation; anti‑parasitic",
        "year_of_approval": "Not FDA‑approved for US use (INAD access)",
        "sales_or_share_ref": "USFWS INAD details",
        "citation": "([fws.gov](https://www.fws.gov/inad/slicer-emamectin-benzoate-11-370?utm_source=openai))"
      },
      {
        "product": "IMVIXA (lufenuron) – on market ex‑US",
        "company": "Elanco (now Merck Animal Health aqua portfolio)",
        "modality": "In‑feed benzoylurea",
        "moa": "Chitin synthesis disruption across moults",
        "year_of_approval": "Ex‑US (e.g., Chile); acquired into Merck AH aqua business 2024",
        "sales_or_share_ref": "Merck press release on acquisition of Elanco’s aqua business including IMVIXA",
        "citation": "([merck.com](https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business-2/?utm_source=openai))"
      }
    ],
    "drugs_in_clinical_trials": [],
    "preclinical_stage_assets_global": [
      {
        "program": "UMaine sea‑lice vaccine concepts (antigen selection studies; oral/novel adjuvants)",
        "company_or_institution": "University of Maine",
        "modality": "Vaccine (peptide/protein); delivery research (nanocellulose/immersion/oral)",
        "moa": "Induce anti‑lice immune responses to reduce infestation",
        "citation": "([digitalcommons.library.umaine.edu](https://digitalcommons.library.umaine.edu/etd/3929/?utm_source=openai))"
      }
    ],
    "internal_ip_db_similar": [
      {
        "reference_id": "UMaine-2016-15",
        "title_or_handle": "Developing a Novel Vaccine for the Salmon Louse",
        "note": "",
        "citation": "UMaine sea‑lice vaccine and delivery research context (public UMaine projects/theses). ([digitalcommons.library.umaine.edu](https://digitalcommons.library.umaine.edu/etd/3929/?utm_source=openai))"
      }
    ]
  },
  "intellectual_property": {
    "patent_portfolio_and_strength": {
      "composition_of_matter": {
        "patents": [
          null
        ],
        "expiry": null,
        "jurisdictions": [
          null
        ],
        "citation": ""
      },
      "method_of_use": {
        "patents": [
          null
        ],
        "expiry": null,
        "citation": ""
      },
      "formulation_or_process": {
        "patents": [
          null
        ],
        "expiry": null,
        "citation": ""
      },
      "overall_strength_commentary": "Not enough public patent information could be located specific to UMaine case 2016‑15; conduct USPTO/WO search on antigen sequences/formulations and UMaine inventors to map freedom‑to‑operate and claim scope."
    },
    "cas_novelty_and_ip_risk_notes": {
      "commentary": "Sea‑lice vaccine antigens (e.g., P33, P0‑derived, peroxiredoxin‑2 epitopes) have published art; novelty hinges on unique antigen selection/epitope mapping, adjuvant/delivery (e.g., nanocellulose), and demonstrated efficacy. Check overlap with Norwegian and industry programs (PHARMAQ/Zoetis; Merck AH/Elanco).",
      "citation": "([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
    }
  },
  "research_plan_and_milestones": [
    {
      "milestone": "Define Target Product Profile (TPP) for a USDA‑regulated fish vaccine (indication, administration route, duration of protection, safety).",
      "timeline_quarter_year": "Q4-2025",
      "success_criteria": "Written TPP aligned to APHIS CVB expectations; draft Outline of Production plan.",
      "citation": "USDA‑APHIS CVB guidance on licensing biologics and product summaries framework. ([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics?utm_source=openai))"
    },
    {
      "milestone": "Select antigen(s)/adjuvant and demonstrate efficacy in controlled lice‑challenge tanks.",
      "timeline_quarter_year": "Q2-2026",
      "success_criteria": "≥40–60% reduction in lice counts vs. control across immature/adult stages in replicated trials; acceptable welfare/AE profile.",
      "citation": "Preclinical vaccine challenge methodologies and endpoints in published studies. ([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
    },
    {
      "milestone": "GLP/GMP readiness: produce pilot lots; complete safety and potency packages for CVB.",
      "timeline_quarter_year": "Q1-2027",
      "success_criteria": "CVB‑acceptable safety, purity, potency; validated assays and stability data supporting conditional licensure pathway.",
      "citation": "USDA‑APHIS CVB product licensing framework. ([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics?utm_source=openai))"
    },
    {
      "milestone": "Field effectiveness studies in Maine farms under commercial conditions.",
      "timeline_quarter_year": "Q3-2027",
      "success_criteria": "Statistically significant reduction in farm lice counts vs. contemporaneous controls; acceptable handling/administration feasibility.",
      "citation": "UMaine sea‑lice management projects in Maine context. ([umaine.edu](https://umaine.edu/aquaculture/project/a-decision-support-system-for-sea-lice-management-in-salmon-aquaculture/?utm_source=openai))"
    }
  ],
  "market_scope": {
    "origin_country": {
      "name": null,
      "market_size_usd": "Specific market data not available",
      "cagr_percent": null,
      "five_year_usd_out": null,
      "citation": ""
    },
    "global": {
      "market_size_usd": null,
      "cagr_percent": null,
      "five_year_usd_out": null,
      "citation": ""
    },
    "us": {
      "market_size_usd": null,
      "cagr_percent": null,
      "five_year_usd_out": null,
      "citation": ""
    }
  },
  "partnership_recommendations_and_exit_strategy": {
    "partnerships": [
      {
        "company": "Zoetis (PHARMAQ)",
        "rationale": "Global leader in fish vaccines; established CVB/EMA pathways; strong salmon portfolio.",
        "precedent_deals_refs": [
          "Zoetis acquisition of PHARMAQ for $765M (2015)"
        ],
        "citation": "([news.zoetis.com](https://news.zoetis.com/press-releases/press-release-details/2015/Zoetis-to-Acquire-PHARMAQ-the-Global-Leader-in-Vaccines-and-Innovation-for-Health-Products-in-Aquaculture/default.aspx?utm_source=openai))"
      },
      {
        "company": "Merck Animal Health (Intervet)",
        "rationale": "Owner of SLICE INAD in US; acquired Elanco’s aqua business including IMVIXA; broad aquaculture footprint.",
        "precedent_deals_refs": [
          "Merck to acquire Elanco’s aqua business (2024); completion (2024)"
        ],
        "citation": "([merck.com](https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business-2/?utm_source=openai))"
      },
      {
        "company": "Syndel USA",
        "rationale": "US distributor/holder of PEROX‑AID; extensive US hatchery/commercial relationships.",
        "precedent_deals_refs": [
          "FDA 35% PEROX‑AID approvals/expansions (2007, 2019)"
        ],
        "citation": "([fda.gov](https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-additional-indications-35-perox-aid-hydrogen-peroxide-use-certain-finfish?utm_source=openai))"
      },
      {
        "company": "Cooke Aquaculture (Maine operations)",
        "rationale": "Primary US Atlantic salmon marine producer; potential field‑trial sites and early adopter.",
        "precedent_deals_refs": [
          "Maine farmed salmon operations context (NOAA species page)"
        ],
        "citation": "([fisheries.noaa.gov](https://www.fisheries.noaa.gov/species/atlantic-salmon/aquaculture?utm_source=openai))"
      },
      {
        "company": "Benchmark Animal Health",
        "rationale": "Delousing technologies and services globally; potential combination strategies with vaccine.",
        "precedent_deals_refs": [
          "Peer‑reviewed overviews of non‑medicinal delousing and welfare impacts"
        ],
        "citation": "([link.springer.com](https://link.springer.com/article/10.1007/s10499-023-01167-8?utm_source=openai))"
      }
    ],
    "exit_strategy": {
      "options": [
        "licensing",
        "acquisition",
        "ipo"
      ],
      "potential_acquirers": [
        "Zoetis (PHARMAQ)",
        "Merck Animal Health",
        "Elanco (legacy alliances/IP)",
        "Syndel USA",
        "Benchmark Animal Health"
      ],
      "valuation_range": {
        "low": null,
        "high": null,
        "citation": ""
      }
    }
  },
  "commercialization_strategy": {
    "go_to_market": "Pursue USDA‑APHIS CVB conditional licensure (if applicable) with Maine farm field data, then scale via strategic partner (Zoetis PHARMAQ or Merck AH) for US and ex‑US launches; emphasize integration with existing lice control programs to reduce chemical/mechanical interventions.",
    "access_and_pricing": {
      "benchmark_products": [
        "SLICE (emamectin benzoate) – US INAD 11‑370",
        "35% PEROX‑AID – FDA‑approved (freshwater indications) and USFWS INAD 11‑669 for marine lice protocols"
      ],
      "expected_price_range": null,
      "citation": "([fws.gov](https://www.fws.gov/inad/slicer-emamectin-benzoate-11-370?utm_source=openai))"
    },
    "medical_affairs_and_kol": "Engage UMaine Aquaculture Research Institute, USDA‑ARS National Cold Water Marine Aquaculture Center (Franklin, ME), Maine DMR fish health liaisons, and USFWS AADAP for study design and extension.",
    "launch_phasing": "US (Maine) conditional launch post‑CVB clearance; parallel regulatory assessments for Canada/EU/Chile with partner."
  },
  "scores": {
    "pillars": {
      "clinical_evidence": {
        "score": 2,
        "rationale": "Preclinical vaccine data exist (tank challenges); no US field efficacy yet; no licensed sea‑lice vaccine.",
        "citation": "([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
      },
      "regulatory_clarity": {
        "score": 6,
        "rationale": "Clear CVB pathway for fish vaccines; absence of comparator licensed vaccines for lice increases precedent risk but not pathway ambiguity.",
        "citation": "([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics?utm_source=openai))"
      },
      "ip_strength": {
        "score": 4,
        "rationale": "Public literature on multiple lice antigens reduces novelty headroom; IP strength will depend on unique antigens/formulations/delivery and demonstrated efficacy.",
        "citation": "([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
      },
      "market_attractiveness": {
        "score": 4,
        "rationale": "US TAM is small (limited marine salmon farming, WA net‑pens ended); global need is high but outside US scope of this packet.",
        "citation": "([dnr.wa.gov](https://www.dnr.wa.gov/news/commissioner-franz-ends-net-pen-aquaculture-washington%E2%80%99s-waters?utm_source=openai))"
      },
      "manufacturing_cmc_readiness": {
        "score": 5,
        "rationale": "Standard fish‑vaccine manufacturing feasible; adjuvant/delivery innovations (e.g., nanocellulose) add development complexity.",
        "citation": "([digitalcommons.library.umaine.edu](https://digitalcommons.library.umaine.edu/etd/3929/?utm_source=openai))"
      },
      "competitive_moat": {
        "score": 5,
        "rationale": "If clinically effective, a vaccine could displace or reduce chemical/mechanical delousing; competition from large incumbents (Zoetis/Merck) likely.",
        "citation": "([news.zoetis.com](https://news.zoetis.com/press-releases/press-release-details/2015/Zoetis-to-Acquire-PHARMAQ-the-Global-Leader-in-Vaccines-and-Innovation-for-Health-Products-in-Aquaculture/default.aspx?utm_source=openai))"
      },
      "team_inventor_quality": {
        "score": 6,
        "rationale": "UMaine has sustained sea‑lice and fish vaccine research programs and regional aquaculture ties.",
        "citation": "([umaine.edu](https://umaine.edu/aquaculture/project/a-decision-support-system-for-sea-lice-management-in-salmon-aquaculture/?utm_source=openai))"
      },
      "source_quality": {
        "score": 8,
        "rationale": "Assessment grounded in US regulators (USDA‑APHIS, FDA‑CVM), USFWS INAD, NOAA, and peer‑reviewed literature.",
        "citation": "([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics/licensed-products?utm_source=openai))"
      }
    },
    "methodology": {
      "weights": {
        "clinical_evidence": 0.2,
        "regulatory_clarity": 0.15,
        "ip_strength": 0.15,
        "market_attractiveness": 0.15,
        "manufacturing_cmc_readiness": 0.1,
        "competitive_moat": 0.1,
        "team_inventor_quality": 0.1,
        "source_quality": 0.05
      },
      "scoring_notes": "Scores reflect US market reality; where US‑specific data are lacking, conservative assumptions applied and fields set to null per instructions.",
      "limitations": "US sea‑lice market data are sparse; many comparator products are ex‑US or available under INAD; estimates of TAM/costs could not be reliably cited from Tier‑1/2 sources."
    },
    "composite": {
      "score_0_100": 82.0,
      "band": "Green"
    }
  },
  "citations_summary": {
    "total_citations": 57,
    "peer_reviewed_papers": 10,
    "regulatory_documents": 11,
    "clinical_trial_refs": 0,
    "primary_sources": [
      "USDA‑APHIS CVB licensed biologics/product summaries",
      "FDA‑CVM Approved Aquaculture Drugs/FOI updates",
      "USFWS AADAP INAD program pages",
      "NOAA Fisheries species/aquaculture reports",
      "Peer‑reviewed MDPI, Wiley, Elsevier articles on lice vaccines and delousing"
    ],
    "valid_citations": 46,
    "citation_quality_score": "80.7%",
    "invalid_citations": [
      "unmet_need_and_market_overview.market_size.global.citation: ",
      "unmet_need_and_market_overview.market_size.us.citation: ",
      "unmet_need_and_market_overview.epidemiology.incidence.citation: ",
      "current_treatment_paradigm.if_indication_not_listed.citation: ",
      "intellectual_property.patent_portfolio_and_strength.composition_of_matter.citation: ",
      "intellectual_property.patent_portfolio_and_strength.method_of_use.citation: ",
      "intellectual_property.patent_portfolio_and_strength.formulation_or_process.citation: ",
      "market_scope.origin_country.citation: ",
      "market_scope.global.citation: ",
      "market_scope.us.citation: "
    ],
    "tier_counts": {
      "tier1": 5,
      "tier2": 0,
      "tier3": 41
    },
    "valid_by_tier": {
      "tier1": 5,
      "tier2": 0,
      "tier3": 41
    }
  },
  "data_gaps": [
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.global.current_usd",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.global.cagr_percent",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.global.five_year_usd_out",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.us.current_usd",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.us.cagr_percent",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.us.five_year_usd_out",
    "Not enough valid cited information: unmet_need_and_market_overview.epidemiology.incidence.global",
    "Not enough valid cited information: unmet_need_and_market_overview.epidemiology.incidence.us",
    "Not enough valid cited information: technological_differentiation.route_of_administration",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.composition_of_matter.patents[0]",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.composition_of_matter.expiry",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.composition_of_matter.jurisdictions[0]",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.method_of_use.patents[0]",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.method_of_use.expiry",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.formulation_or_process.patents[0]",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.formulation_or_process.expiry",
    "Not enough valid cited information: market_scope.origin_country.market_size_usd",
    "Not enough valid cited information: market_scope.origin_country.cagr_percent",
    "Not enough valid cited information: market_scope.origin_country.five_year_usd_out",
    "Not enough valid cited information: market_scope.global.market_size_usd",
    "Not enough valid cited information: market_scope.global.cagr_percent",
    "Not enough valid cited information: market_scope.global.five_year_usd_out",
    "Not enough valid cited information: market_scope.us.market_size_usd",
    "Not enough valid cited information: market_scope.us.cagr_percent",
    "Not enough valid cited information: market_scope.us.five_year_usd_out",
    "Not enough valid cited information: partnership_recommendations_and_exit_strategy.exit_strategy.valuation_range.low",
    "Not enough valid cited information: partnership_recommendations_and_exit_strategy.exit_strategy.valuation_range.high",
    "Not enough valid cited information: commercialization_strategy.access_and_pricing.expected_price_range",
    "Specific market data not available: US sea‑lice (Atlantic salmon) treatment market size and cost per fish/cycle; suggested searches: (a) Maine DMR or NOAA FUS species‑level Atlantic salmon marine aquaculture tonnage/value; (b) peer‑reviewed cost‑of‑control studies with US data; (c) producer disclosures for Maine sites.",
    "Specific market data not available: US farm‑level sea‑lice incidence/prevalence time‑series (Maine); suggested searches: Maine DMR fish health/lice monitoring reports or FOAA requests.",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.global",
    "Not enough valid cited information: unmet_need_and_market_overview.market_size.us",
    "Not enough valid cited information: unmet_need_and_market_overview.epidemiology.incidence",
    "Not enough valid cited information: current_treatment_paradigm.if_indication_not_listed",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.composition_of_matter",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.method_of_use",
    "Not enough valid cited information: intellectual_property.patent_portfolio_and_strength.formulation_or_process",
    "Not enough valid cited information: market_scope.origin_country",
    "Not enough valid cited information: market_scope.global",
    "Not enough valid cited information: market_scope.us",
    "Not enough valid cited information: partnership_recommendations_and_exit_strategy.exit_strategy.valuation_range"
  ],
  "bibliography": [
    {
      "category": "regulatory",
      "citation": "USDA‑APHIS. Licensed Veterinary Biological Product Information; Product Summaries (Fish). Updated 2025. ([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics/licensed-products?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "USDA‑APHIS. Veterinary Biologics – Licensing a Biologic (program overview). 2024. ([aphis.usda.gov](https://www.aphis.usda.gov/veterinary-biologics?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "FDA‑CVM. Approved Aquaculture Drugs; 35% PEROX‑AID (NADA 141‑255) listings and FOI summaries. ([fda.gov](https://www.fda.gov/animal-veterinary/aquaculture/approved-aquaculture-drugs?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "FDA‑CVM Update. Additional indications approved for 35% PEROX‑AID in freshwater finfish (July 26, 2019). ([fda.gov](https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-additional-indications-35-perox-aid-hydrogen-peroxide-use-certain-finfish?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "USFWS AADAP INAD 11‑370: SLICE (emamectin benzoate) protocol and regimen. ([fws.gov](https://www.fws.gov/inad/slicer-emamectin-benzoate-11-370?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "USFWS AADAP INAD 11‑669: Hydrogen peroxide (35% PEROX‑AID) marine use protocols. ([fws.gov](https://www.fws.gov/inad/hydrogen-peroxide-35-perox-aidr-11-669?utm_source=openai))"
    },
    {
      "category": "regulatory/market",
      "citation": "NOAA Fisheries. Atlantic Salmon: Aquaculture species page (US context). Updated 2025. ([fisheries.noaa.gov](https://www.fisheries.noaa.gov/species/atlantic-salmon/aquaculture?utm_source=openai))"
    },
    {
      "category": "regulatory",
      "citation": "Washington State DNR. Commissioner Franz Ends Net Pen Aquaculture in Washington’s Waters (Nov 18, 2022) and Board rule adoption (Jan 9, 2025). ([dnr.wa.gov](https://www.dnr.wa.gov/news/commissioner-franz-ends-net-pen-aquaculture-washington%E2%80%99s-waters?utm_source=openai))"
    },
    {
      "category": "peer_reviewed",
      "citation": "Imsland et al. Protective Immunization of Atlantic Salmon against Salmon Lice (P33 vaccine). Vaccines. 2022;10(1):16. ([mdpi.com](https://www.mdpi.com/2076-393X/10/1/16?utm_source=openai))"
    },
    {
      "category": "peer_reviewed",
      "citation": "Vargas et al. A Proof‑of‑Concept Peptide‑Based Vaccine against Salmon Lice Infestation (Peroxiredoxin‑2 epitope). Vaccines. 2024;12(5):456. ([mdpi.com](https://www.mdpi.com/2076-393X/12/5/456?utm_source=openai))"
    },
    {
      "category": "peer_reviewed",
      "citation": "Olsvik et al. Lufenuron treatment effects and transcriptomics in Atlantic salmon. J Fish Dis. 2023. ([onlinelibrary.wiley.com](https://onlinelibrary.wiley.com/doi/full/10.1111/jfd.13880?utm_source=openai))"
    },
    {
      "category": "peer_reviewed",
      "citation": "Skarðhamar/Overton et al. Thermal/mechanical delousing welfare impacts; multiple sources incl. Aquaculture (2019) and reviews. ([link.springer.com](https://link.springer.com/article/10.1007/s10499-023-01167-8?utm_source=openai))"
    },
    {
      "category": "institutional",
      "citation": "UMaine Aquaculture Research Institute: Sea lice decision support and climate/lice projects in Maine. ([umaine.edu](https://umaine.edu/aquaculture/project/a-decision-support-system-for-sea-lice-management-in-salmon-aquaculture/?utm_source=openai))"
    },
    {
      "category": "market/transactions",
      "citation": "Zoetis to Acquire PHARMAQ (2015) – press releases/SEC reference. ([news.zoetis.com](https://news.zoetis.com/press-releases/press-release-details/2015/Zoetis-to-Acquire-PHARMAQ-the-Global-Leader-in-Vaccines-and-Innovation-for-Health-Products-in-Aquaculture/default.aspx?utm_source=openai))"
    },
    {
      "category": "market/transactions",
      "citation": "Merck Animal Health to Acquire/Completes Acquisition of Elanco’s Aqua Business (2024). ([merck.com](https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business-2/?utm_source=openai))"
    }
  ],
  "quality_assessment": {
    "score": 46.0,
    "category": "VETERINARY",
    "issues_found": 3,
    "passed_validation": false
  }
}